Tissue distribution and abuse potential of prucalopride: findings from non-clinical and clinical studies
Background: Prucalopride is a selective serotonin type 4 (5-HT4) receptor agonist indicated for treatment of chronic idiopathic constipation (CIC) in adults (2 mg orally, daily). 5-HT4 receptors are present in the central nervous system; therefore, non-clinical and clinical assessments were performe...
Main Authors: | Katayoun Derakhchan, Zhen Lou, Hong Wang, Robert Baughman |
---|---|
Format: | Article |
Language: | English |
Published: |
BioExcel Publishing Ltd
2023-02-01
|
Series: | Drugs in Context |
Subjects: | |
Online Access: | https://www.drugsincontext.com/tissue-distribution-and-abuse-potential-of-prucalopride-findings-from-non-clinical-and-clinical-studies/ |
Similar Items
-
Antipsychotics induced constipation in patients with mental disorders. treatment suggestion with prucalopride in refractory cases. case report and literature review
by: P. Mpouras, et al.
Published: (2022-06-01) -
Design of a phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of prucalopride in pediatric patients with functional constipation
by: Carmen Cuffari, et al.
Published: (2023-06-01) -
Safety/Efficacy of Prucalopride in Korean Patients with Chronic Constipation: Post-marketing Surveillance
by: Sang Eun Yeon, et al.
Published: (2022-10-01) -
An Open-Label, Head to Head Comparison Study between Prucalopride and Lactulose for Clozapine Induced Constipation in Patients with Treatment Resistant Schizophrenia
by: Ishwary Damodaran, et al.
Published: (2020-12-01) -
Drug abuse handbook /
by: Karch, Steven B.
Published: (2007)